SystImmune is a leading and well-funded clinical-stage biopharmaceutical company located in Redmond, WA and Princeton, NJ. It specializes in developing innovative cancer treatments using its established drug development platforms, focusing on bi-specific, multi-specific antibodies, and antibody-drug conjugates (ADCs). SystImmune has multiple assets in various stages of clinical trials for solid tumor and hematologic indications. Alongside ongoing clinical trials. SystImmune has a robust preclinical pipeline of potential cancer therapeutics in the discover and IND-enabling stages, representing cutting-edge biologics development. We offer an opportunity for you to learn and grow while making significant contributions to the company's success.
We are looking for a creative and motivated individual to execute and improve our Computational Protein Design pipeline using data-driven approaches to augment our first-in-class multi-specific biological programs. The ideal candidate will have experience applying computational methods to design novel peptides and proteins, with expertise in structural modeling, prediction, and optimization.
Responsibilities:
- Execute a computational design pipeline for predicting the properties of peptides, natural ligands, de novo proteins, and antibody-based elements via data-driven approach
- Drive assay validation, tech transfer, and development initiatives to maintain industry standards; Contribute within the computational protein design group to operate yeast display-based protein discovery platforms
- Design new macromolecular therapeutics using structural and sequence analysis, and employ these in silico predictions to iteratively guide the lead development process
- Analyze, interpret, document, and present data to the scientific and leadership team
- Collaborate with our Antibody Discovery, Protein Engineering, and Immuno-oncology teams to contribute to the company's vision
Qualifications:
- PhD (or equivalent) in bioengineering, biophysics, biochemistry, molecular biology, cell biology, or a related field
- 8+ years of experience using yeast libraries to generate protein binding or therapeutic antibodies required
- Experience with relevant macromolecular modeling software (e.g., AlphaFold, RoseTTAFold, RFdiffusion, ProteinMPNN, Gromacs, MOE, Schrödinger)
- Expertise in screening and ranking of antibodies (ELISA, multi-parametric flow cytometry, BLI/OCTET)
- Proven contribution to therapeutic antibody development and selection is desirable; design and validation of novel biologically relevant antibodies are highly desirable
Compensation and Benefits:
The expected base salary range for this position is $80,000 - $180,000 annually. Actual compensation will be based on a variety of factors, including but not limited to a candidate’s qualifications, experience, and skills.
While most offers typically fall within the low to mid-point of the range, we may extend an offer toward the higher end for exceptional candidates whose background and expertise exceeds the requirements of the role.
SystImmune is a leading and well-funded biotech company with a bright future. We offer an opportunity for you to learn and grow while making significant contributions to the company’s success. SystImmune offers a comprehensive benefits package including: 100% paid employee premiums for medical/dental/vision, also STD, LTD, a 401(k) plan with a 50% company match of up to 3% and a vesting schedule of only 5 years, 15 PTO days per year, sick leave, plus 11 paid holidays and MORE.
We offer an opportunity for you to learn and grow while making significant contributions to the company’s success.
SystImmune is an Equal Opportunity Employer. We welcome diverse talent and encourage all qualified applicants to apply.
Top Skills
What We Do
Located in Redmond WA, founded in 2014, Systimmune Inc. is a bio-pharmaceutical company focused on the treatment of cancer through developing novel therapeutic bi-specific, and tri-specific antibodies, as well as antibody-drug conjugates (ADC's). Our objective is to create biologics that work through systematic intervention on the solid tumor micro-environment, to either directly attack the tumor and/or to activate the immune system to attack the tumor. We are a group of highly experienced immuno-oncology scientists utilizing several technology platforms to develop world class advanced antibody-based drug therapies.
